HIV-associated pulmonary arterial hypertension: From bedside to the future

European Journal of Clinical Investigation

Volumn 45, Issue 5, 2015, Pages 515-528

  Correale, Michele ^a   Palmiotti, Giuseppe Antonio ^a   Lo Storto, Maria Maddalena ^a   Montrone, Deodata ^a   Foschino Barbaro, Maria Pia ^a   Di Biase, Matteo ^a   Lacedonia, Donato ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

HIV; AIDS; Pulmonary arterial hypertension; Pulmonary hypertension

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; DRUG INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; COMPLICATION; HIV INFECTIONS; HYPERTENSION, PULMONARY; PROCEDURES;

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY;

EID: 84928320643     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12427     Document Type: Article

References (102)

1. Monsuez JJ, Charniot JC, Escaut L, Teicher E, Wyplosz B, Couzigou C et al.HIV-associated vascular diseases: structural and functional changes, clinical implications. Int J Cardiol 2009;133:293-306.
2. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-38.
3. Gottlieb MS, Schanker HM, Fan PT, Saxon A, Weisman JD. Pneumocystis pneumonia Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2.
4. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
5. Barré-Sinoussi F. HIV as the cause of AIDS. Lancet 1996;348:31-35.
6. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw-Hill; 2008: pp 1107-9.
7. Ray N, Doms RW. HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 2006;303:97-120.
8. Smith JA, Daniel R. Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses. ACS Chem Biol 2006;1:217-26.
9. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006;368:489-504.
10. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, Markowitz M et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001;194:1277-87.
11. Knoll B, Lassmann B, Temesgen Z. Current status of HIV infection: a review for non-HIV-treating physicians. Int J Dermatol 2007;46:1219-1228.
12. Almodovar S, Cicalini S, Petrosillo N, Flores SC. Pulmonary vascular disease: the global perspective. Chest 2010;137(Suppl.):6S-12S.
13. Herskowitz A. Cardiomyopathy and other symptomatic heart diseases associated with HIV infection. Curr Opin Cardiol 1996;11:325-31.
14. Singer EJ, Valdes-Sueiras M, Commins DL, Yong W, Carlson M. HIV stroke risk: evidence and implications. Ther Adv Chronic Dis 2013;4:61-70.
15. Boccara F, Cohen A, Di AE, Meuleman C, Ederhy S, Dufaitre G et al. Coronary artery bypass graft in HIV-infected patients: a multicenter case control study. Curr HIV Res 2008;6:59-64.
16. Myerson M, Poltavskiy E, Armstrong EJ, Kim S, Sharp V, Bang H. Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 HIV outpatients. J Acquir Immune Defic Syndr 2014;66:370-7.
17. Saber AA, Aboolian A, LaRaja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg 2001;67:645-7.
18. Guyot S, Hayoz D, Telenti A, Cavassini M. Peripheral oedema and high arterial blood flow as a complication of antiretroviral therapy. AIDS 2004;18:356-8.
19. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
20. Opravil M, Pechère M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155:990-5.
21. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
22. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30.
23. Pellicelli AM, Palmieri F, D'Ambrosio C, Rianda A, Boumis E, Girardi E et al. Role of human immunodeficiency virus in primary pulmonary hypertension-case reports. Angiology 1998;49:1005-11.
24. Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998;73:37-45.
25. Weiss JR, Pietra GG, Scharf SM. Primary pulmonary hypertension and the human immunodeficiency virus. Report of two cases and a review of the literature. Arch Intern Med 1995;155:2350-4.
26. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11:554-9.
27. Himelman RB, Dohrmann M, Goodman P, Schiller NB, Starksen NF, Warnock M et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 1989;64:1396-9.
28. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-71.
29. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108-13.
30. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133-41.
31. Pellicelli AM, Barbaro G, Palmieri F, Girardi E, D'Ambrosio C, Rianda A et al. Primary pulmonary hypertension in HIV patients: a systematic review. Angiology 2001;52:31-41.
32. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 2008;22(Suppl. 3):S35-40.
33. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433-9.
34. Marti'n-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, Gonza'lez-Lahoz J et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011;25:1305-15.
35. Petitpretz P, Brenot F, Azarian R, Parent F, Rain B, Herve P et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994;89:2722-7.
36. Correale M, Montrone D, Lacedonia D, Ieva R, Bucci R, Corrado A et al. Multiprofessional and intrahospital experience for diagnosis and treatment of pulmonary arterial hypertension. Monaldi Arch Chest Dis 2012;78:205-9.
37. Cicalini S, Chinello P, Petrosillo N. HIV infection and pulmonary arterial hypertension. Expert Rev Respir Med 2011;5:257-66.
38. Degano B, Guillaume M, Savale L, Montani D, Jaïs X, Yaici A et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010;24:67-75.
39. Kanmogne GD, Kennedy RC, Grammas P. Analysis of human lung endothelial cells for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. AIDS Res Hum Retroviruses 2001;17:45-53.
40. Barnett CF, Hsue PY. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med 2013;34:283-92.
41. Morse JH, Barst RJ, Itescu S, Flaster ER, Sinha G, Zhang Y et al. Primary pulmonary hypertension in hiv infection an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996;153:1299-U01.
42. Kim J, Ruff M, Karwatowska-Prokopczuk E, Hunt L, Ji H, Pert CB et al. HIV envelope protein gp120 induces neuropeptide Y receptor mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Regul Pept 1998;75-76:201-5.
43. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005;333:1107.
44. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-85.
45. Mermis J, Gu H, Xue B, Li F, Tawfik O, Buch S et al. Hypoxia-inducible factor-1 a/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res 2011;12:103.
46. Almodovar S, Hsue PY, Morelli J, Huang L, Flores SC. Pulmonary hypertension potential role of HIV-1 nef. HIV study. Proc Am Thorac Soc 2011;8:308-12.
47. Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF. HIV-1 Nef Is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006;174:437-45.
48. Almodovar S, Knight R, Allshouse AA, Roemer S, Lozupone C, McDonald D et al. Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retroviruses 2012;28:607-18.
49. Parikh RV, Scherzer R, Nitta EM, Leone A, Hur S, Mistry V et al. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. AIDS 2014;28:511-9.
50. Dhillon NK, Li F, Xue B, Tawfik O, Morgello S, Buch S et al. Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction. Am J Respir Cell Mol Biol 2011;45:40-52.
51. Dalvi P, Wang K, Mermis J, Zeng R, Sanderson M, Johnson S et al. HIV-1/cocaine induced oxidative stress disrupts tight junction protein-1 in human pulmonary microvascular endothelial cells: role of Ras/ERK1/2 pathway. PLoS One 2014;9:e85246.
52. Dalvi P, O'Brien-Ladner A, Dhillon NK. Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2013;33:2585-95; 5.
53. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006;92:1164-6.
54. Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38:1178-85.
55. Quezada M, Martin-Carbonero L, Soriano V, Vispo E, Valencia E, Moreno V et al. Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. AIDS 2012;26:1387-92.
56. Syed FF, Sani MU. Recent advances in HIV-associated cardiovascular diseases in Africa. Heart 2013;99:1146-53.
57. Ntsekhe M, Hakim J. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 2005;112:3602-7.
58. Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat Clin Pract Cardiovasc Med 2009;6:120-7.
59. Makubi A, Hage C, Lwakatare J, Kisenge P, Makani J, Rydén L et al. Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. Heart 2014;100:1235-41.
60. Zhou YH, Liu FL, Yao ZH, Duo L, Li H, Sun Y et al. Comparison of HIV-, HBV-, HCV- and co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border region. PLoS One 2011;6:e16349.
61. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al. Guidelines for the diagnosis and treatment of pulmonary hypertension ESC/ERS. Eur Heart J 2009;30:2493-537.
62. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11.
63. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40.
64. Cea-Calvo L, Escribano Subias P, Tello de Menesses R, Lazaro Salvador M, Gomez Jimenez MA, Delgado Jimenez JF et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol 2003;56:421-5.
65. Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004;23:321-6.
66. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142:1383-90.
67. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846-50.
68. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212-7.
69. Degano B, Yaïci A, Le Pavec J, Savale L, Jaïs X, Camara B et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009;33:92-8.
70. Zacà V, Metra M, Danesi R, Lombardi C, Verzura G, Dei Cas L. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Ther Adv Respir Dis 2009;3:11-4.
71. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-9.
72. Farber HB, Gillies H, Allard M, Blair C. Long term ambrisentan therapy in patients with HIV infection: a meta-analysis from the ambrisentan studies. Am J Respir Crit Care Med 2012;185:A4783.
73. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35.
74. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30:93-9.
75. Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:1971-81.
76. Chinello P, Cicalini S, Cortese A, Cicini MP, Petrosillo N. Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension. Infect Dis Rep 2011;3:e14.
77. Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002;16:1568-9.
78. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001;15:1747-8.
79. Wong AR, Rasool AH, Abidin NZ, Noor AR, Quah BS. Sildenafil as treatment for human immunodeficiency virus-related pulmonary hypertension in a child. J Paediatr Child Health 2006;42:147-8.
80. Alp S, Schlottmann R, Bauer TT, Schmidt WE, Bastian A. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003;17:1714-5.
81. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903.
82. Araújo I, Enjuanes-Grau C, Lopez-Guarch CJ, Narankiewicz D, Ruiz-Cano MJ, Velazquez-Martin T et al. Pulmonary arterial hypertension related to human immunodeficiency virus infection: a case series. World J Cardiol 2014;6:495-501.
83. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809-18.
84. Hardy H, Backman ES, Farber HW. Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. Pharmacotherapy 2010;30:139e-44e.
85. Dai HL, Lu YB, Guang XF, Xiao ZC, Zhang M, Zhang WH. Bosentan and antiretroviral therapy in an HIV/HBV/HCV coinfected Chinese patient with HIV-related pulmonary arterial hypertension. Chin Med J (Engl) 2013;126:1197-8.
86. Spangler ML, Saxena S. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli. Clin Ther 2010;32:53-6.
87. Murphey LM, Hood EH. Bosentan and warfarin interaction. Ann Pharmacother 2003;37:1028-31.
88. Morales-Molina JA, Martínez-de lPJ, Urquízar-Rodríguez O, Molina-Arrebola MA. Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far. Hematol Rep 2011;3:e16.
89. Llibre JM, Romeu J, López E, Sirera G. Severe Interaction Between Ritonavir and Acenocoumarol. Ann Pharmacother 2002;36:621-3.
90. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43:1089-115.
91. Rane A, Lindh JD. Pharmacogenetics of anticoagulants. Hum Genomics Proteomics 2010;2010:754919.
92. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60.
93. Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R. Evaluation of the endothelin receptor antagonists, ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 2010;88:682-91.
94. Guo Y, Weller P, Farrell E, Cheung P, Fitch B, Clark D et al. In silico pharmacogenetics: warfarin metabolism. Nat Biotechnol 2006;24:531-6.
95. Aschmann YZ, Kummer O, Linka A, Wenk M, Azzola A, Bodmer M et al. Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors. Ther Drug Monit 2008;30:130-4.
96. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Clin Pharmacol 2000;50:99-107.
97. Garraffo R, Lavrut T, Ferrando S, Durant J, Rouyrre N, MacGregor TR et al. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol 2011;51:1071-8.
98. Dellegrottaglie S, García-Alvarez A, Guarini P, Perrone-Filardi P, Fuster V, Sanz J. Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension. Heart Lung 2014;43:256-61.
99. Amsellem V, Lipskaia L, Abid S, Poupel L, Houssaini A, Quarck R et al. CCR5 as a treatment target in pulmonary arterial hypertension. Circulation 2014;130:880-91.
100. Sharma M, Pinnamaneni S, Aronow WS, Jozwik B, Frishman WH. Existing drugs and agents under investigation for pulmonary arterial hypertension. Cardiol Rev 2014;22:297-305.
101. Savale L, Sattler C, Günther S, Montani D, Chaumais MC, Perrin S et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2014;44:1627-34.
102. Sangal RB, Taylor LE, Gillani F, Poppas A, Klinger JR, Ventetuolo CE. Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection. Ann Am Thorac Soc 2014;11:1553-9.